Filing identity and reporting period
Major metadata discrepancy: The supplied filing is for Rosewind Corporation, not AYTU Biopharma, Inc. It covers the unaudited three months ended November 30, 2014 (the company’s fiscal first quarter of 2015) and was signed January 12, 2015. The financial statement amounts are presented in dollars.
Business context and financial results
Rosewind described its business as teaching offshore sailing. It reported no revenue in either the quarter ended November 30, 2014 or the comparable 2013 quarter. Management said the company had earned $6,250 in total net revenue from prior training voyages.
- Quarterly net loss was $15,754, versus $16,507 a year earlier; loss from operations was $15,291 versus $15,007.
- Operating expenses were $15,291, compared with $15,007. Interest expense declined to $463 from $1,500.
- Basic and diluted loss per share was reported as $(0.00) in both periods.
- Net cash used in operating activities was $9,327, versus $6,858. Financing provided $16,008, including $15,000 from a common-stock sale and $1,008 of related-party loans. Cash increased by $6,681 to $8,996.
Liquidity, debt, and capital
- At November 30, 2014, current assets were $9,319 and current liabilities were $55,243, producing a reported working capital deficit of $45,924. Total assets were $11,150; shareholders’ equity was negative $44,093.
- Related-party loans payable were $31,993, and accrued related-party interest was $18,070. The note to the sole officer and director bears 6% interest, is secured by the sailing vessel, and is payable on demand.
- The company issued 100,000 shares for $15,000 during the quarter. Shares outstanding were 5,835,402 at November 30, 2014 and January 12, 2015.
- Management stated that available cash was insufficient to sustain the business and planned to seek additional equity financing; there is no assurance it could raise funds.
Changes, outlook, and risks
The net loss narrowed by $753 (approximately 5%) year over year, as lower boat repair, maintenance, and docking costs and lower interest expense were partly offset by higher professional fees and management expense. Cash was higher than at August 31, 2014, primarily reflecting the stock sale and related-party borrowing; operating activities continued to consume cash.
The filing gives no quantified revenue or profitability guidance. Management said student revenue remained unproven and described evaluating a possible additional business unrelated to sailing, but reported no decision or definitive agreement. The company disclosed substantial doubt about its ability to continue as a going concern, citing losses, limited operating history, and dependence on generating cash or obtaining additional funding.
Other disclosed risks include limited market acceptance, regulatory and licensing uncertainty across jurisdictions, potentially significant public-company costs, dependence on one officer/director, conflicts of interest, and inadequate vessel and liability insurance. The company also described possible California and local property-tax obligations; it reported paying $310 to resolve an Alameda County vessel-tax matter and including an $800 annual California business-tax expense allowance.
Important facts for investors to verify
- Confirm the filing is the intended document: its registrant is Rosewind Corporation, not AYTU Biopharma, Inc.
- Verify the reporting-period mapping: the filing covers the three months ended November 30, 2014, not a calendar-year first quarter.
- Assess the going-concern warning, cash needs, and the availability and terms of any future financing.
- Review the demand loan, accrued interest, security interest in the vessel, and related-party arrangements.
- Check the status of the proposed business-plan change, applicable operating licenses and taxes, and the adequacy of insurance.